Clinical Trial Update: Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing FOLFIRI plus zimberelimab and domvanalimab versus FOLFIRI with a synthetic control arm in second-line neuroendocrine carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma of Unknown Primary Origin
• Neuroendocrine Carcinoma of the Gastrointestinal Tract

Drugs mentioned

• Domvanalimab (domvanalimab)
• FOLFIRI (folinic acid, fluorouracil, irinotecan) (FOLFIRI)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Carcinoma, Neuroendocrine | Phase 2 | Status: NOT_YET_RECRUITING